Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.
2.

High prices for generics in Australia - more competition might help.

Bulfone L.

Aust Health Rev. 2009 May;33(2):200-14.

PMID:
19563309
3.

Generics market in Greece: the pharmaceutical industry's beliefs.

Geitona M, Zavras D, Hatzikou M, Kyriopoulos J.

Health Policy. 2006 Nov;79(1):35-48. Epub 2005 Dec 28.

PMID:
16386326
4.

Generic drugs: international trends and policy developments in Australia.

Lofgren H.

Aust Health Rev. 2004;27(1):39-48.

PMID:
15362295
5.

The effect of generic competition on the price of brand-name drugs.

Lexchin J.

Health Policy. 2004 Apr;68(1):47-54.

PMID:
15033552
6.

Impact of European pharmaceutical price regulation on generic price competition: a review.

Puig-Junoy J.

Pharmacoeconomics. 2010;28(8):649-63. doi: 10.2165/11535360-000000000-00000. Review.

PMID:
20515079
7.

Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.

Kong Y.

Health Econ. 2009 May;18(5):591-606. doi: 10.1002/hec.1392.

PMID:
18816580
8.

[Price differences between generic and innovator medicines in Brazil].

Vieira FS, Zucchi P.

Rev Saude Publica. 2006 Jun;40(3):444-9. Epub 2006 Jun 23. Portuguese.

9.

The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.

Kwon HY, Kim H, Godman B, Reich MR.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):1007-14. doi: 10.1586/14737167.2015.1083425. Epub 2015 Sep 22.

PMID:
26394767
10.

Competition and the Reference Pricing Scheme for pharmaceuticals.

Ghislandi S.

J Health Econ. 2011 Dec;30(6):1137-49. doi: 10.1016/j.jhealeco.2011.08.010. Epub 2011 Sep 3.

PMID:
21937137
11.

High Generic Drug Prices and Market Competition: A Retrospective Cohort Study.

Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A.

Ann Intern Med. 2017 Aug 1;167(3):145-151. doi: 10.7326/M16-1432. Epub 2017 Jul 4.

PMID:
28672324
12.

Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.

Andersson K, Petzold MG, Sonesson C, Lönnroth K, Carlsten A.

Health Policy. 2006 Dec;79(2-3):231-43. Epub 2006 Feb 13.

PMID:
16473436
13.

Lipid-lowering drugs: use and expenditure in Portugal (1995-2004).

Teixeira IJ, Escoval A, Schiappa M.

Rev Port Cardiol. 2007 May;26(5):475-93. English, Portuguese.

14.

Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.

McManus P, Birkett DJ, Dudley J, Stevens A.

Pharmacoepidemiol Drug Saf. 2001 Jun-Jul;10(4):295-300.

PMID:
11760489
15.

The impact of generic reference pricing interventions in the statin market.

Puig-Junoy J.

Health Policy. 2007 Nov;84(1):14-29. Epub 2007 Mar 26.

PMID:
17368619
16.

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.

Coma A, Zara C, Godman B, Agustí A, Diogène E, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):569-81. doi: 10.1586/erp.09.58. Review.

PMID:
19941434
17.

Reference pricing of pharmaceuticals.

Brekke KR, Königbauer I, Straume OR.

J Health Econ. 2007 May 1;26(3):613-42. Epub 2006 Dec 22.

PMID:
17188769
19.

Reference pricing with endogenous generic entry.

Brekke KR, Canta C, Straume OR.

J Health Econ. 2016 Dec;50:312-329. doi: 10.1016/j.jhealeco.2016.04.003. Epub 2016 Jun 8.

PMID:
27350294
20.

The impact of reference-pricing systems in Europe: a literature review and case studies.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729-37. doi: 10.1586/erp.11.70. Review.

PMID:
22098289

Supplemental Content

Support Center